|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Maryland Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MarylandLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Profectus BioSciences, Inc.
| | | Phone: | (443) 743-1107 | Fax: | (443) 633-5709 | Year Established: | 2003 | Main Contact: | Jeffrey Meshulam, President | | Other Contacts: | Shawn Patrick O'Brien, President & CEO Timothy R. Fouts, Ph.D., Director, Research and Development
| | Company Description | Profectus BioSciences is a clinical-stage vaccine development company developing preventive and therapeutic vaccines for infectious diseases and oncolytic vaccines for cancer immunotherapy. Profectus vaccines are based on the company’s proprietary VesiculoVax™ and DNA vaccine delivery platforms. Used alone, first-in-class VesiculoVax™-vectored vaccines lead to rapid expansion of B cells to provide protection against emerging infectious diseases of public health and biodefense importance such as Ebola, Marburg, Chikungunya, and the Equine Encephalitis viruses. When used as a boost after priming the immune system with best-in-class pDNA vaccines, VesiculoVax™-vectored vaccines lead to the expansion of primed T cells into effector cells that are uniquely suited to killing virally infected cells and cancers. | |
|
|
|
|
|